濮阳东方医院看妇科好不好(濮阳东方看妇科可靠吗) (今日更新中)

With a total of six adopted and foster children, Keri Penland’s family is an exercise in planning and patience.“Trying to do school with them has been insane,” she said.All of her kids are school-aged; some have learning disabilities. When the coronavirus pandemic hit, they--along with tens of millions of other students across the country--became part of a nationwide experiment in remote learning.Her verdict?“I don't know how anybody is doing this, to be honest,” Penland said. “It's not possible.”And it turns out, she's not alone.“We found that remote learning is really failing our most vulnerable learners,” said Justin Ruben, who is with the nonprofit “ParentsTogether.” The group recently conducted a survey of more than 1,500 families across the country to see how remote learning was going.Among the findings:When compared to a family making 0,000 a year, lower-income families--making ,000 or less-- are ten times more likely to have children doing little to no remote learning.Those families are also five times more likely to attend a school not offering distance learning materials at all and 13 percent of them didn’t even have a computer device or internet access.Yet, the numbers were even worse for families of children with special needs, who usually get individualized support at school. Out of those families, 40 percent said that with remote learning, they were receiving no support at all.“A huge chunk of students are being left behind by remote learning,” Ruben said.ParentsTogether wants the federal government to step in with 5 billion more in funding for education, especially since the coronavirus pandemic slashed tax revenues for local and state budgets and, in turn, education programs.“Schools are making budgets right now and kids are falling behind right now, and schools are making plans for the fall right now,” Ruben said. “And so, there's this surreal lack of urgency in Washington, D.C., and there’s literally like a whole generation of vulnerable kids is being allowed to languish.”Back at Penland’s house, it’s been an unusual ending to the school year.“I'll tell you, if school doesn't start again, the kids are gonna be way, way behind,” she said. “It's a different time than we've ever experienced.”Given everything that happened with schools and the pandemic, experts have some suggestions for how to keep kids engaged and learning over the summer.Keep some semblance of structure. A visual schedule that everyone can see will help and make it easier for you and your kids to get back into the swing of things when summer ends.Read to your children or encourage them to read, write or draw--anything that engages their minds, as long as it does not involve a computer or phone screen.Outdoor hikes, walks or scavenger hunts can help kids get exercise and keep them engaged in discovering new things.Make sure your kids get enough sleep and proper nutrition, to keep them in top shape and ready for when it’s time to return to school. 2998

WEST PALM BEACH, Fla. — Michael Womer is known as the "Gator Crusader." He posts wild videos where he gets extremely close to alligators during live shows. He said he's loved alligators since he was a child and even told his school counselor in high school he already knew he wanted to perform with gators as a teenager.He shared what he's been doing differently during the pandemic, and if he thinks alligators can sense the difference.Womer performs with a gator show in central Florida and he shares videos of his wildest antics online. He often dresses up, performs stunts and even reads to the alligators. He's perhaps most widely known for a video where he falls into a gator pit when his rope swing snaps.Womer said the alligators can tell something is different because there aren’t as many people around. 821

White House press secretary Sarah Sanders privately berated the White House communications and press staff Friday after a leak the previous day of comments by aide Kelly Sadler about Sen. John McCain, according to several sources familiar with the meeting.In discussing McCain's opposition to CIA nominee Gina Haspel, Sadler,?a special assistant who handles surrogate communications for the White House, said in a private meeting Thursday that it doesn't matter "because he's dying anyway." It was a joke that fell flat, a White House official told CNN. 571

What color is your county and state?The Harvard Global Health Institute released an interactive map on Wednesday that shows the risk of contracting the coronavirus based on daily new cases per 100,000 people.Based on Harvard's guidelines, three US states need to implement stay-at-home orders, while an additional 13 should consider them. The map has four colors – green, yellow, orange and red – to demonstrate the risk by county and state. The map shows three states – Arizona, Florida and Mississippi – in the red for where infections are high. Just two states – Hawaii and Vermont—are in the green. While Hawaii requires face coverings in public setting such as retailers despite being one of only two states without community spread, the three states in red have not implemented mandatory face coverings in public. "We've left it to the locals to make decisions about whether they want to use coercive measures or impose any type of criminal penalties. We're not going to do that statewide," Florida Gov. Ron DeSantis said on Tuesday.According to Harvard Global Health Institute, when areas are shaded red, stay-at-home orders become necessary. So far, Arizona, Florida and Mississippi have not reinstituted stay-at-home orders despite being in the red. Arizona and Florida did announce that most bars can no longer serve alcohol on site.“The public needs clear and consistent information about COVID risk levels in different jurisdictions for personal decision-making, and policy-makers need clear and consistent visibility that permits differentiating policy across jurisdictions”, said Danielle Allen, director of the Edmond J. Safra Center for Ethics at Harvard University. “We also collectively need to keep focused on what should be our main target: a path to near zero case incidence.”Thirteen states are in the orange, meaning those states should consider either implementing stay-at-home orders or conduct rigorous tracing programs, Harvard said..“Local leaders need and deserve a unified approach for suppressing COVID-19, with common metrics so that they can begin to anticipate and get ahead of the virus, rather than reacting to uncontrolled community spread”, says Beth Cameron, Vice President for Global Biological Policy and Programs at the Nuclear Threat Initiative and a member of the COVID-Local.org team. “Unless and until there is a whole of government response, with measurable progress communicated similarly and regularly across every state and locality, U.S. leaders will be left to react to the chaos of the virus - rather than being able to more effectively target interventions to suppress it. “COVID RISK LEVEL: GREEN- Less than one case per 100,000 people- On track for containment- Monitor with viral testing and contact tracing programCOVID RISK LEVEL: YELLOW- 1-9 cases per 100,000 people- Community spread- Rigorous test and trace programs advisedCOVID RISK LEVEL: ORANGE- 10-24 cases per 100,000 people- Accelerated spread- Stay-at-home orders and/or rigorous test and trace programs advisedCOVID RISK LEVEL: RED- 25 or more cases per 100,000 people- Tipping point- Stay-at-home orders necessaryClick here to view the map. 3170

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

来源：资阳报